ArticleJournal of virology2026
Establishment of an oral enterovirus 71 (EV71) infection model in immunocompetent mice for antiviral therapy evaluation.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Enterovirus 71 (EV71) is one of the major pathogens responsible for hand-foot-and-mouth disease in children and is associated with severe neurological complications, including death. Despite the fact that EV71 naturally infects humans through the oral route, the absence of a simple and reliable oral infection model has significantly impeded investigations into its pathogenesis and the development of antiviral interventions. In this study, we established a robust oral EV71 infection model in widely used immunocompetent BALB/c mice, employing a clinical isolate devoid of adaptive mutations. Mice infected via the oral route developed disease progression and clinical, as well as pathological features that closely recapitulate those observed in human infection. We further identified marked differences in viral dissemination and host immune responses between oral and intraperitoneal inoculation, underscoring the importance of physiologically relevant oral infection models for elucidating EV71 pathogenesis. In addition, the anti-EV71 candidate drug rupintrivir showed reduced efficacy in the oral infection model compared with the intraperitoneal model. Notably, this oral model enables evaluation of therapies designed to block intestinal viral infection-a capability lacking in intraperitoneal models. Using this platform, we assessed an intestinal probiotic blockade therapy for the first time. Our findings demonstrate that the probiotic formulation effectively suppresses viral replication and alleviates pathological damage in the spleen, lungs, kidneys, and other organs, providing a scientific basis for developing probiotic-based therapeutic strategies against viral infections. IMPORTANCE: The restricted host tropism of enterovirus 71 (EV71) has limited the development of animal models that accurately recapitulate human disease. Here, we demonstrate for the first time that the clinically isolated EV71-GZCII strain successfully infects 14-day-old immunocompetent BALB/c mice via oral gavage, establishing a physiologically relevant model that addresses this critical gap. Orally infected mice displayed distinct viral dissemination patterns and host immune responses compared with intraperitoneal models, highlighting the critical role of infection route in EV71 pathogenesis. Using this system, we evaluated the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.